Premium
World Workshop on Oral Medicine VII: Biomarkers predicting lymphoma in the salivary glands of patients with Sjögren’s syndrome—A systematic review
Author(s) -
Delli Konstantina,
Villa Alessandro,
Farah Camile S.,
Celentano Antonio,
Ojeda David,
Peterson Douglas E.,
Jensen Siri Beier,
Glurich Ingrid,
Vissink Arjan
Publication year - 2019
Publication title -
oral diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.953
H-Index - 87
eISSN - 1601-0825
pISSN - 1354-523X
DOI - 10.1111/odi.13041
Subject(s) - medicine , critical appraisal , biomarker , lymphoma , confounding , medline , oncology , systematic review , pathology , alternative medicine , biology , biochemistry
Objective To conduct a systematic review of studies exploring potential biomarkers for development, course, and efficacy of treatment of lymphomas in salivary glands of patients with Sjögren's syndrome. Material and Methods Eligible studies were identified through a comprehensive search of two databases, that is, PubMed and EMBASE. Quality of included articles was assessed with the “Quality In Prognosis Studies” (QUIPS) tool. The “CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies” (CHARMS) was used to facilitate data extraction. Results Fifty‐eight studies met the inclusion criteria. Only one study assessed the progression of lymphoma. Moderate risk of bias was detected in “outcome measurement,” “study participation,” and “study confounding” domains. Parotid gland enlargement, mixed monoclonal cryoglobulins, and low C4 levels represented strongest predictors of lymphoma development. The role of histological biomarkers, and specifically germinal centers, remains controversial. Clinical and methodological heterogeneity across studies precluded conduct of a meta‐analysis. Conclusions Specific biomarkers in combination with clinical manifestations represent potential candidates for advancing precision medicine approaches to lymphoma prediction in patients with Sjögren's syndrome. Current focus has increasingly been on genetic and epigenetic markers as candidate predictors. Predictive accuracy of key biomarker candidates remains to be tested in well‐designed prospectively followed Sjögren's syndrome cohorts.